Stay updated on Vemurafenib+Cobimetinib Beyond Progression in BRAF+ Melanoma Clinical Trial

Sign up to get notified when there's something new on the Vemurafenib+Cobimetinib Beyond Progression in BRAF+ Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Vemurafenib+Cobimetinib Beyond Progression in BRAF+ Melanoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T06:27:59.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page has undergone significant content removal, particularly regarding the detailed description of a study on the efficacy of vemurafenib combined with cobimetinib for treating metastatic melanoma. Key information about the study's purpose, inclusion and exclusion criteria, and the principal investigator has been deleted.
    Difference
    25%
    Check dated 2025-04-16T20:54:59.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.14.4, with the removal of several sections related to disease attributes, pathologic processes, and disease progression.
    Difference
    0.2%
    Check dated 2025-04-09T16:08:21.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-02T00:40:31.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1.0%
    Check dated 2025-02-24T23:20:30.000Z thumbnail image
  8. Check
    87 days ago
    Change Detected
    Summary
    The web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1%
    Check dated 2025-02-10T17:18:29.000Z thumbnail image

Stay in the know with updates to Vemurafenib+Cobimetinib Beyond Progression in BRAF+ Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Vemurafenib+Cobimetinib Beyond Progression in BRAF+ Melanoma Clinical Trial page.